GlassScriptPhysician profile
Corey Lee Greene
NPI 1881454601
$963.26
in general payments reported to CMS, 2019-2025
13 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $548 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.26 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $263.64 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $204.58 | 2024-2025 | Biktarvy |
| Theratechnologies INC. | $98.44 | 2024 | Egrifta Sv, Trogarzo, Egrifta |
| Axsome Therapeutics, INC. | $76.95 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $66.40 | 2024-2025 | Spravato |
| Abbvie INC. | $60.67 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.71 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $37.25 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $31.02 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $24.81 | 2025 | Airsupra |
| Exact Sciences Corporation | $19.69 | 2024 | Cologuard Collection Kit |
| Aurinia Pharma U.S., INC. | $17.99 | 2024 | Lupkynis |
| Amgen INC. | $16.11 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.